Citigroup Maintains Neutral on Hims & Hers Health, Raises Price Target to $28

Benzinga Newsdesk www.benzinga.com Neutral 52.6%

Neg 0% Neu 52.6% Pos 0%

Citigroup analyst Daniel Grosslight maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and raises the price target from $24 to $28.